伊马替尼治疗新发1型糖尿病:多中心随机双盲安慰剂对照2期试验
这项多中心随机双盲安慰剂对照2期试验纳入新发1型糖尿病成人患者,评估伊马替尼26周疗程对β细胞功能的影响。结果显示12个月时伊马替尼组2小时C肽AUC调整均值差为0·095(90% CI -0·003至0·191;p=0·048,单侧检验),达到主要终点,但效果未能维持至24个月,且不良反应更常见。
要点
- 伊马替尼26周疗程在12个月时保留新发1型糖尿病成人β细胞功能。
- 该效应未能持续至24个月。
- 伊马替尼组≥2级不良事件及因不良事件停药比例更高。
核心结论
- 26周伊马替尼疗程在12个月时保留新发1型糖尿病成人的β细胞功能。
- 伊马替尼可能为改变1型糖尿病病程提供新途径。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照2期试验,在美国8个和澳大利亚1个中心开展。
- 纳入新发1型糖尿病(确诊<100天)、年龄18-45岁、至少一种糖尿病相关自身抗体阳性、混合餐耐量试验(MMTT)刺激后C肽峰值>0·2 nmol/L的患者。
- 按2:1随机分配接受伊马替尼甲磺酸盐400 mg/日(4×100 mg薄膜衣片)或匹配安慰剂治疗26周,按中心分层区组随机。
- 主要终点为12个月时MMTT前2小时C肽反应曲线下面积(AUC)均值在伊马替尼组与安慰剂组间的差异,采用ANCOVA模型调整性别、基线年龄和基线C肽。
- 共45例分配至伊马替尼组、22例至安慰剂组;12个月主要意向性治疗(ITT)分析纳入伊马替尼组43例、安慰剂组21例。
主要发现
- 12个月时伊马替尼组与安慰剂组2小时C肽AUC调整均值差为0·095(90% CI -0·003至0·191;p=0·048,单侧检验),达到主要终点。
- 该效应未能维持至24个月。
- 24个月随访期间,伊马替尼组45例中32例(71%)发生≥2级不良事件,安慰剂组22例中13例(59%)。
- 组间差异最常见的≥2级不良事件为胃肠道问题(伊马替尼组6例[13%],主要为恶心;安慰剂组0例)和额外实验室检查(伊马替尼组10例[22%],安慰剂组2例[9%])。
- 按试验方案,伊马替尼组17例(38%)需临时调整药物剂量、6例(13%)因不良事件永久停用伊马替尼;安慰剂组5例(23%)临时调整剂量、0例因不良事件永久停药。
关键数值与推荐
- 主要终点达到:12个月2小时C肽AUC调整均值差0·095(90% CI -0·003至0·191;p=0·048,单侧检验)。
- 入组标准包括:确诊<100天、年龄18-45岁、至少一种糖尿病相关自身抗体阳性、MMTT刺激后C肽峰值>0·2 nmol/L。
- 干预方案:伊马替尼甲磺酸盐400 mg/日或匹配安慰剂,疗程26周。
临床怎么用
- 对于新发1型糖尿病成人患者,26周伊马替尼疗程可能有助于在12个月时保留β细胞功能。
- 使用伊马替尼需仔细监测可能的毒性,尤其是胃肠道不良反应和实验室检查异常。
- 伊马替尼的的理想剂量、疗程、在儿童中的安全性和有效性、与互补药物联用以及在高危人群中延缓或预防糖尿病进展的能力尚需未来研究确定。
局限性
- 主要终点效应未能维持至24个月。
- 伊马替尼组≥2级不良事件及因不良事件永久停药的比例高于安慰剂组。
- 研究仅纳入18-45岁成人,未评估儿童中的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Patients with recent-onset type 1 diabetes (<100 days from diagnosis), aged 18-45 years, positive for at least one type of diabetes-associated autoantibody, and with a peak stimulated C-peptide of greater than 0·2 nmol L-1 on a mixed meal tolerance test (MMTT) were enrolled from nine medical centres in the USA (n=8) and Australia (n=1). Participants were randomly assigned (2:1) to receive either 400 mg imatinib mesylate (4 × 100 mg film-coated tablets per day) or matching placebo for 26 weeks via a computer-generated blocked randomisation scheme stratified by centre. Treatment assignments were masked for all participants and study personnel except pharmacists at each clinical site. The primary endpoint was the difference in the area under the curve (AUC) mean for C-peptide response in the first 2 h of an MMTT at 12 months in the imatinib group versus the placebo group, with use of an ANCOVA model adjusting for sex, baseline age, and baseline C-peptide, with further observation up to 24 months. The primary analysis was by intention to treat (ITT). Safety was assessed in all randomly assigned participants. This study is registered with ClinicalTrials.gov, NCT01781975 (completed). FINDINGS: Patients were screened and enrolled between Feb 12, 2014, and May 19, 2016. 45 patients were assigned to receive imatinib and 22 to receive placebo. After withdrawals, 43 participants in the imatinib group and 21 in the placebo group were included in the primary ITT analysis at 12 months. The study met its primary endpoint: the adjusted mean difference in 2-h C-peptide AUC at 12 months for imatinib versus placebo treatment was 0·095 (90% CI -0·003 to 0·191; p=0·048, one-tailed test). This effect was not sustained out to 24 months. During the 24-month follow-up, 32 (71%) of 45 participants who received imatinib had a grade 2 severity or worse adverse event, compared with 13 (59%) of 22 participants who received placebo. The most common adverse events (grade 2 severity or worse) that differed between the groups were gastrointestinal issues (six [13%] participants in the imatinib group, primarily nausea, and none in the placebo group) and additional laboratory investigations (ten [22%] participants in the imatinib group and two [9%] in the placebo group). Per the trial protocol, 17 (38%) participants in the imatinib group required a temporary modification in drug dosing and six (13%) permanently discontinued imatinib due to adverse events; five (23%) participants in the placebo group had temporary modifications in dosing and none had a permanent discontinuation due to adverse events. INTERPRETATION: A 26-week course of imatinib preserved β-cell function at 12 months in adults with recent-onset type 1 diabetes. Imatinib might offer a novel means to alter the course of type 1 diabetes. Future considerations are defining ideal dose and duration of therapy, safety and efficacy in children, combination use with a complimentary drug, and ability of imatinib to delay or prevent progression to diabetes in an at-risk population; however, careful monitoring for possible toxicities is required. FUNDING: Juvenile Research Diabetes Foundation.
引用
- Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021. PMID: 34214479. doi:10.1016/S2213-8587(21)00139-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。